UTime Limited (FXHO) declined roughly 38% over the past 30 days, falling from about $9.10 in mid-October to near $5.62, with the last completed close at $5.50. The selloff has been driven by thin liquidity, elevated post-reverse-split volatility, a "Sell" rating action, and persistent revenue contraction and net losses in the company's core handset business.

Intel (INTC) shares fell roughly 41% over the last 30 days, sliding from a closing price of $98.12 on October 14, 2026, to about $57.63 at the latest reading. The sharpest move came on October 30, 2026, when the stock dropped nearly 29% in a single session following weaker-than-expected fourth-quarter guidance.

PGEN shares fell roughly 38% over the trailing 30 days, with the decline accelerating in early November. The sharpest single-session move came after the FDA approved a competing recurrent respiratory papillomatosis (RRP) therapy from Inovio , sending PGEN down about 25%.

Inter & Co (INTR) shares have fallen roughly 40% over the past 30 days, sliding from about $6.99 in mid-October to near $4.20, as Brazilian financial assets repriced sharply. The move was triggered by Luiz Inácio Lula da Silva's unexpected presidential runoff victory, which renewed concerns about fiscal policy, interest rates, and regulation in Brazil.

IMXI shares fell roughly 39% over the last 30 days, sliding from about $10.53 to about $6.39 per share, with further weakness in the most recent session. The selloff centered on the unraveling of Western Union 's (WU) roughly $500 million acquisition of Intermex, originally announced at $16.00 per share.

ENHA shares fell roughly 42% over the last 30 days, sliding from a split-adjusted close near $11.70 in mid-October to around $6.80. The decline reflects a post-merger repricing of a young, cash-consuming business, amplified by a 1-for-10 reverse stock split that took effect October 29, 2026.

PRA Group shares declined roughly 41% over the trailing 30 days, with most of the drop compressed into a single session following its third-quarter earnings release. The catalyst was a Q3 2026 earnings miss: GAAP diluted EPS of $0.39 and revenue of $286.3 million both came in below consensus expectations.

Boost Run (BRUN) has declined roughly 46.5% over the last 30 days, from a closing price of $9.65 to about $5.16, extending a steep multi-month downtrend. The selloff reflects a broad repricing of AI and data-center stocks, compounded by share-supply overhang and questions about how quickly contract value converts into revenue.

Velo3D shares fell roughly 40% over the past 30 days, extending a longer multi-month downtrend in the small-cap industrial technology space. Third-quarter 2026 revenue rose about 50% year over year to $20.5 million and beat estimates, but an adjusted loss of $0.34 per share missed analyst expectations.

Applied Optoelectronics (AAOI) shares fell roughly 43.9% over the 30-day period through mid-November 2026, sliding from around $86 to near $48 as a sector-wide AI-optics selloff compounded a guidance-driven decline. The company posted record third-quarter revenue of $269.9 million, up 127.5% year over year, and returned to GAAP profitability — but fourth-quarter revenue guidance landed below analyst consensus.

BKKT shares declined roughly 41% over the last 30 days, falling from a closing price near $5.98 to about $3.51. Third-quarter 2026 revenue fell 62.9% year over year to $149.2 million as cryptocurrency trading volume declined.

ImmunityBio (IBRX) shares fell about 38.7% over the last 30 days, from $9.91 to roughly $6.07, extending a pullback that also leaves the stock down about 20.7% over the trailing quarter. The sharpest leg down followed third-quarter 2026 results on November 9, when revenue missed estimates and net product sales declined sequentially for the first time in nine quarters.

IREN shares fell roughly 42% over the trailing 30 days, dropping from about $30.56 to around $17.70. The decline extends a longer pullback: the stock is down about 60% over the trailing quarter.

CHWM has fallen roughly 44% over the last 30 days, sliding from about $5.43 to approximately $3.05, extending a decline since its October 2026 Nasdaq debut. The American Depositary Shares are newly listed, so the recent period largely reflects early post-listing price discovery in a thinly traded market.

XRPN has fallen roughly 44% over the last 30 days, sliding from a $15.26 close on October 14, 2026, to about $8.50 as the post-listing surge fully unwound. The decline follows a sharp, short-lived rally around the company's Nasdaq debut after it completed its business combination with Armada Acquisition Corp. II.

Starling Oncology (STLN) shares fell roughly 45% over the past 30 days, from about $6.51 to near $3.58, with most of the decline occurring in a single trading session. The selloff followed a third-quarter 2026 earnings miss, as the company posted a wider-than-expected loss of $0.13 per share versus a consensus estimate near $0.05.

Veracyte (VCYT) shares fell roughly 45.5% over the last 30 days, driven by a sharp selloff after the company's third-quarter 2026 earnings report. The stock plunged about 54% in a single session after management reset growth expectations for its flagship Decipher Prostate test and trimmed forward guidance.

Bicara Therapeutics (BCAX) declined roughly 43.6% over the trailing 30 days, driven chiefly by a single-session collapse on October 28, 2026. The selloff was triggered by positive Phase 3 data from Genmab for a competing head and neck cancer therapy, sharpening the competitive threat to Bicara's lead candidate.

BR Partners (BRBI) shares have declined roughly 50% over the past 30 days, sliding from about $15.30 to near $7.60 per American depositary share. The sharpest single-session drop followed the issuance of R$124.2 million in perpetual subordinated notes by a subsidiary, a move investors interpreted as a signal of dilution and liquidity risk.

MNTN, Inc. shares have fallen roughly 46.6% over the last 30 days, driven primarily by a sharp selloff following third-quarter 2026 results. On November 4, 2026, the company reported Q3 revenue of $80.3 million, below its own guidance range of $86 million to $89 million and below consensus estimates.